BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Core Viewpoint - BioNTech SE has appointed Kylie Jimenez as Chief People Officer, effective March 1, 2026, to support its strategy of becoming a multi-product oncology company by 2030, emphasizing the importance of its global workforce in achieving this goal [1][3] Group 1: Appointment Details - Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy, focusing on talent attraction, development, retention, and fostering an inclusive culture [1] - Jimenez has over 20 years of experience in global HR, previously serving as CHRO at Georg Fischer and holding roles at Toyota, Johnson & Johnson, and General Mills [2] - Her appointment reflects BioNTech's commitment to operational excellence and long-term value creation for shareholders, employees, and patients [3] Group 2: Company Background - BioNTech is a global immunotherapy company focused on developing novel therapies for cancer and serious diseases, utilizing a range of computational discovery and therapeutic modalities [5] - The company has a diversified oncology product pipeline, including mRNA cancer immunotherapies, immunomodulators, and targeted therapies like antibody-drug conjugates and CAR T cell therapies [5] - BioNTech collaborates with various global pharmaceutical companies, including Bristol Myers Squibb, Pfizer, and Genentech, to advance its research and development efforts [5]